Nutanix stock jump 14% after earnings beat, strong revenue guidance
By Paul Ziobro
Shares of Nutanix (NTNX) rose after the cloud-software company posted better-than-expected quarterly results and projected revenue for the current year ahead of Wall Street estimates.
The stock was up 14.1% to $59.64 in late trading after closing the regular trading session at $52.29. Through Wednesday's close, the stock had been up about 9.7% this year.
The San Jose, Calif.-based company posted a fiscal fourth-quarter loss of $126.1 million, or 51 cents a share, compared with a loss of $13.3 million, or 6 cents a share, in the year-ago quarter. Adjusted for one-time items, per-share earnings were 27 cents, ahead of the 20 cents expected by analysts recently polled by FactSet.
Revenue rose 11% to $548 million. Analysts expected $536.9 million.
For the current year, Nutanix expects revenue between $2.44 billion and $2.47 billion. Analysts were looking for $2.44 billion.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-28-24 1837ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks